1. The earlier, the better: the effects of different administration timepoints of sorafenib in suppressing the carcinogenesis of VEGF in rats
- Author
-
Dai Haitao, Yonghui Huang, Bin Chen, Jianyong Yang, Keyu Tang, Run Lin, Ni Liu, and Nan Li
- Subjects
Oncology ,Vascular Endothelial Growth Factor A ,Cancer Research ,Time Factors ,Carcinogenesis ,H&E stain ,Toxicology ,medicine.disease_cause ,Rats, Sprague-Dawley ,chemistry.chemical_compound ,0302 clinical medicine ,Liver Neoplasms, Experimental ,Medicine ,Pharmacology (medical) ,Mice, Inbred BALB C ,Sorafenib ,Immunohistochemistry ,Up-Regulation ,Vascular endothelial growth factor ,030220 oncology & carcinogenesis ,Heterografts ,030211 gastroenterology & hepatology ,Original Article ,Overall survival time ,medicine.drug ,medicine.medical_specialty ,Liver tumor ,Microvessel density ,Mice, Nude ,Antineoplastic Agents ,Drug Administration Schedule ,03 medical and health sciences ,Statistical significance ,Internal medicine ,Cell Line, Tumor ,Animals ,Pharmacology ,business.industry ,medicine.disease ,Survival Analysis ,Rats ,Regimen ,chemistry ,Microvessels ,business - Abstract
Purpose To investigate the optimal starting time point of sorafenib therapy in suppressing the tumor-promoting effects of VEGF up-regulation, which is frequently found after local therapy in clinical practice. Methods VEGF was intravenously injected to imitate the evaluated expression after local tumor therapy, such as TACE. A total of 40 SD rats bearing hepatic tumors were randomly divided into four groups and sorafenib was administered at different timepoints: (A) control group: VEGF injection only; (B) initiating sorafenib 72 h prior to VEGF injection; (C) initiating sorafenib simultaneously with VEGF injection; (D) initiating sorafenib 72 h post-VEGF injection. The rate of tumor growth, median survival time, expression of VEGF, and microvessel density (MVD), as determined by immunohistochemical (IHC) examination, were compared. Results The results revealed that the tumor size and median survival time were significantly different between the three sorafenib groups compared to the control group (p
- Published
- 2017